Antitumor activity in RAS-driven tumors by blocking AKT and MEK. - Wikidata - wikimedia - TriplyDB

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

http://www.wikidata.org/entity/Q35103514

about

Mutant HRAS as novel target for MEK and mTOR inhibitors Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Maximising the potential of AKT inhibitors as anti-cancer treatments The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells.Targeting RAS-mutant cancers: is ERK the key?A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).Selumetinib for the treatment of non-small cell lung cancer.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Selumetinib in the treatment of non-small-cell lung cancer.NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.Understanding and targeting resistance mechanisms in NSCLC.miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK.Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer.Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.MEK inhibitors for the treatment of NRAS mutant melanoma Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

P2860

Q27853238-C8FF8450-CF83-4173-B469-A3F1DD9E21BD Q27853310-51D2A5E8-A08D-4E02-A6A9-2D6E55080CD2 Q27853330-06723FC3-517E-49A8-98ED-013FCC296203 Q28072254-789216A1-0822-48E5-8AA6-4880193DDC6B Q28076402-275E97FB-326D-460B-A2B9-9149E0571B52 Q28833740-5694045A-6A11-4796-AE04-ADE275712A47 Q30008980-133BD6A1-5438-4E16-85C7-09D8F611C0B2 Q35775241-A53F7B86-9D36-437C-B207-4D00E36FD32C Q36398735-A4D3809B-82D0-48A7-9489-8472315838B4 Q37203121-28E34904-EF00-4DEF-A902-282A2F0F4FFE Q37417255-84249349-9BC4-4568-A940-E75C4A5FAAC5 Q38267209-CA63C265-BB25-4053-8045-F042E2E8B22F Q38382173-AB635255-0197-4AFD-A040-AD31843101B3 Q38383457-977A77C6-7D0A-4307-8E90-77ED0AA74CB3 Q38387061-1E5A6430-E9F4-4F0B-9B32-5205D37EB80B Q38663069-E3EDCA80-9B14-4C67-8878-1A0C56D051B9 Q38682370-25A8FDE6-3AF9-48D6-8975-A0458D6DE148 Q38734451-13A8EDBA-ABC9-49B2-B24A-E8BCCB7DC7DD Q38740315-EF80B3F4-CEE2-4E85-8863-975DC9E9E45E Q38836927-0BD66A34-5891-492B-AEBE-9DCF4B849F05 Q39400435-1471D406-ACD0-474E-B38E-9591CF06AFEB Q39888234-FF5FA2E6-C2D4-467D-AC28-BCBA0679D002 Q40989800-7B482D3E-6113-49CE-AFDB-297557DD9C87 Q41697013-9469EED3-364E-478D-BF3B-41CCC0F3E881 Q41777292-7B99C55E-2998-461F-8914-0A82C5B63612 Q42370827-D59159C3-739D-49F3-8DD5-6C964C9FDFC1 Q42382909-CCD4AC93-39D6-4BD3-82F4-E9BD350578D9 Q46915997-C4E7309A-5834-417A-B486-F9E6CD4F06C8 Q47103533-65C7A24F-41C6-466B-8B2B-60B5ACCBCE94 Q48234356-FC71CF99-61E4-4424-8F78-942657EF3174 Q54949177-3FA6501C-1437-4D44-99FA-EE66D56E0F49 Q56889985-6DD60008-2AD2-4FAE-A350-9780B3D0BDAE Q58786537-9CF0EFC3-C34F-406D-BC28-D0CAE99B6189

P2860

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

http://www.wikidata.org/entity/Q35103514

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@ast

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@en

type

label

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@ast

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@en

prefLabel

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@ast

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@en

P1433

Q35103514-6E06A0A2-80CD-481C-820F-7E2FE3692EDE

P1476

Q35103514-DE197F83-7959-49DD-97EB-A6CD5F7C9ABD

P2093

Q35103514-07326E6A-B8F1-40B8-9917-D45B76E59DB8

Q35103514-0996EC46-DE41-4CF3-B7CC-817D629593C6

Q35103514-1949E02D-B9D5-444F-BB00-041A4AEE57EA

Q35103514-1984B235-852A-4010-9690-9A8619A47B89

Q35103514-1985775F-5FA8-4A64-B9FD-A24F28107D90

Q35103514-1E4A45A6-C82A-4D82-BA5C-1284514556B8

Q35103514-32BEC7AC-0717-4A48-9D12-6C014FF88F1E

Q35103514-33186A56-CBBD-415D-B602-16630CFF1DEF

Q35103514-54099831-AF05-4BA0-AA72-EB18EAEDFEBB

Q35103514-5B149302-2EEB-49DE-9F53-A9BE41C3EA54

P2860

Q35103514-02ADAAE7-765C-4166-8BD4-28995DDE37FE

Q35103514-08BF9E2B-1630-4636-A387-0B797092D308

Q35103514-110F3F25-F444-4445-BD77-82B2D7768939

Q35103514-144DAE8A-AD09-4278-BBB0-F2B8B53A0DD9

Q35103514-1E31EFAD-DA19-45CC-B180-CBB95F453415

Q35103514-21D917A5-B6A3-414B-A921-6D877DF248AB

Q35103514-3245C80F-8373-45E3-9D75-92B0FE4AA379

Q35103514-3290F82D-4294-4D2E-8531-129DCCB10FA5

Q35103514-392F4A11-7C1B-4740-99D1-D1DDB6DCFC74

Q35103514-505C888E-1550-4955-84B6-489966FF9D96

P304

Q35103514-D7490D89-85D8-431B-9226-6ECBFCDFDA36

P31

Q35103514-FABDD425-81E8-45D8-9F8D-44CD6FDCF95A

P356

Q35103514-99AA9EFB-1564-431E-B184-128B40F674E2

P407

Q35103514-8FE01863-8D56-4AB7-8D61-D798175EC31B

P433

Q35103514-83C883EF-3D8B-48CE-9400-2F850070C19B

P478

Q35103514-B0ED85F6-4565-4BE4-9B34-6BC30BAA5A73

P50

Q35103514-52D99DA0-C546-4784-835A-E2B496C37346

Q35103514-6DD1ECB8-478A-4135-888B-F933BDA141D6

Q35103514-ABBAA63F-F1EA-4843-B126-04C0CC3DBAD8

Q35103514-CA5F27FE-80A2-4282-85E7-9379BDA189CA

P577

Q35103514-612743A6-A241-43A3-A9D0-EE919B2DC5CC

P698

Q35103514-7DA7327E-41FD-4A98-B2DB-CE375C67D3E3

P932

Q35103514-3FD8E170-BC6B-4B54-8BF9-C758300C86C9

P356

1078-0432.CCR-14-1901

P1433

Clinical Cancer Research

P1476

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

@en

P2093

Amita Patnaik

http://www.w3.org/2001/XMLSchema#string

Anne Morosky

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Brianne Kaiser

http://www.w3.org/2001/XMLSchema#string

Christopher R Garrett

http://www.w3.org/2001/XMLSchema#string

David Olmos

http://www.w3.org/2001/XMLSchema#string

David R Gandara

http://www.w3.org/2001/XMLSchema#string

Eric H Rubin

http://www.w3.org/2001/XMLSchema#string

Ernestina Tetteh

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Skolnik

http://www.w3.org/2001/XMLSchema#string

P2860

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Targeting RAS signalling pathways in cancer therapy

RAS oncogenes: weaving a tumorigenic web

P304

739-748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1901

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25516890

http://www.w3.org/2001/XMLSchema#string

P932

4335074

http://www.w3.org/2001/XMLSchema#string